Fungal infections of the CNS: Treatment strategies for the immunocompromised patient

CNS Drugs

Volumn 21, Issue 4, 2007, Pages 293-318

  Black, Katharine E ^a,b   Baden, Lindsey R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DOFETILIDE; ERGOTAMINE DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MIDAZOLAM; PHENYTOIN; POSACONAZOLE; QUINIDINE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; SULFONYLUREA; TACROLIMUS; TERBINAFINE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ACIDOSIS; ANEMIA; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCOSIS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; FEVER; HEART ARREST; HEART ARRHYTHMIA; HISTOPLASMOSIS; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; KIDNEY DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; MENINGITIS; META ANALYSIS; MORBIDITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PATHOGENICITY; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTIFUNGAL AGENTS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 34247115507     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721040-00004     Document Type: Review

References (154)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001 Sep 1; 33 (5): 641-7
2. Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003 Nov; 53 (11): 744-50
3. Pagano L, Gleissner B, Fianchi L. Breakthrough zygomycosis and voriconazole. J Infect Dis 2005 Oct 15; 192 (8): 1496-7; author reply 7
4. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 Apr 1; 34 (7): 909-17
5. Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005 Nov; 131 (3): 287-300
6. Gottfredsson M, Perfect JR. Fungal meningitis. Semin Neurol 2000; 20 (3): 307-22
7. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003 Oct 15; 102 (8): 2768-76
8. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003 May 1; 167 (9): 1279-82
9. Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000 Jun; 30 (6): 851-6
10. Hampson FG, Ridgway EJ, Feeley K, et al. A fatal case of disseminated zygomycosis associated with the use of blood glucose self-monitoring equipment. J Infect 2005; 51 (5): E269-72
11. Doctor Fungus: your on-line reference to all things mycological [online]. Available from URL: http:www.doctorfungus.com [Accessed 2006 Oct 30]
12. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999 Dec; 1 (4): 247-61
13. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005 May 1; 40 Suppl. 6: S414-21
14. Surash S, Tyagi A, De Hoog GS, et al. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med Mycol 2005 Aug; 43 (5): 465-72
15. Fothergill AW. Identification of dematiaceous fungi and their role in human disease. Clin Infect Dis 1996 May; 22 Suppl. 2: S179-84
16. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996 Jul; 23 (1): 125-30
17. De Medeiros BC, de Medeiros CR, Werner B, et al. Central nervous system infections following bone marrow transplantation: an autopsy report of 27 cases. J Hematother Stem Cell Res 2000 Aug; 9 (4): 535-40
18. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005 Jan; 18 (1): 163-94
19. Bleggi-Torres LF, de Medeiros BC, Neto JZ, et al. Disseminated Fusarium sp. infection affecting the brain of a child after bone marrow transplantation. Bone Marrow Transplant 1996 Nov; 18 (5): 1013-5
20. Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005 Jun 1; 103 (11): 2334-7
21. Gilbert D, Moellering Jr RC, Eliopoulos GM, et al. The Sanford guide to antimicrobial therapy 2006. 36th ed. Sperryville (VA): Antimicrobial Therapy, Inc., 2006
22. Den Hollander JG, van Arkel C, Rijnders BJ, et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006 Jun; 57 (6): 1248-50
23. Girmenia C, Cimino G, Di Cristofano F, et al. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Support Care Cancer 2005 Dec; 13 (12): 987-92
24. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 Mar 10; 322 (7286): 579-82
25. Wenzel R, Del Favero A, Kibbler C, et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005 Mar; 55 (3): 352-61
26. Martino R, Cortes M, Subira M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005 Oct; 46 (10): 1429-35
27. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003 Oct 1; 37 Suppl. 3: S157-87
28. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 Aug 8; 347 (6): 408-15
29. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006 May; 12 (5): 552-9
30. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 Mar 1; 34 (5): 563-71
31. Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis 2004 Oct 15; 39 (8): 1241-4
32. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005 Dec; 5 (12): 775-85
33. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4): 335-47
34. Cornely OA, Maertens M, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4): 348-59
35. Denning DW. Echinocandin antifungal drugs. Lancet 2003 Oct 4; 362 (9390): 1142-51
36. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001 Nov; 55 (9): 633-8
37. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003 Jun 1; 36 (11): 1445-57
38. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 Dec 19; 347 (25): 2020-9
39. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006; 106 (2): 466-73
40. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004 Oct 15; 39 (8): 1253-4
41. Bennett JE, Dismukes WE, Duma RJ. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-31
42. Elias Jr J, dos Santos AC, Carlotti Jr CG, et al. Central nervous system paracoccidioidomycosis: diagnosis and treatment. Surg Neurol 2005; 63 Suppl. 1: S13-21; discussion S21
43. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 Jan 15; 38 (2): 161-89
44. Marty FM, Barouch DH, Coakley EP, et al. Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol 2003 Nov; 41 (11): 5317-20
45. Lipton SA, Hickey WF, Morris JH, et al. Candidal infection in the central nervous system. Am J Med 1984 Jan; 76 (1): 101-8
46. Voice RA, Bradley SF, Sangeorzan JA, et al. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994 Jul; 19 (1): 60-6
47. McCullers JA, Vargas SL, Flynn PM, et al. Candidal meningitis in children with cancer. Clin Infect Dis 2000 Aug; 31 (2): 451-7
48. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000 Jul; 37 (3): 169-79
49. Verduyn Lunel FM, Voss A, Kuijper EJ, et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. J Clin Microbiol 2004 Feb; 42 (2): 867-70
50. Go JL, Kim PE, Ahmadi J, et al. Fungal infections of the central nervous system. Neuroimaging Clin N Am 2000 May; 10 (2): 409-25
51. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3)beta-D-glucan) assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 Sep 1; 41 (5): 654-9
52. Kato A, Takita T, Furuhashi M, et al. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001 Sep; 89 (1): 15-9
53. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1→3)-{beta}-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005 Dec; 43 (12): 5957-62
54. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 Oct 22-28; 366 (9495): 1435-42
55. Litvintseva AP, Kestenbaum L, Vilgalys R, et al. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol 2005 Feb; 43 (2): 556-64
56. Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004 Dec 7; 101 (49): 17258-63
57. Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004 Sep; 53 (Pt 9): 935-40
58. Chaturvedi S, Dyavaiah M, Larsen RA, et al. Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis 2005 Nov; 11 (11): 1686-92
59. Chen SC. Australasian Society for Infectious Diseases (ASID) Mycoses Interest Group. Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B. J Antimicrob Chemother 2002 Feb; 49 Suppl. 1: 57-61
60. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994 Dec; 19 (6): 1029-33
61. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30 (4): 710-8
62. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001 Sep 1; 33 (5): 690-9
63. Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985 Oct; 103 (4): 533-8
64. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002 May 3; 16 (7): 1031-8
65. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999 Feb; 28 (2): 291-6
66. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000 Jan; 30 (1): 47-54
67. Barenfanger J, Lawhorn J, Drake C. Nonvalue of culturing cerebrospinal fluid for fungi. J Clin Microbiol 2004 Jan; 42 (1): 236-8
68. Guermazi A, Gluckman E, Tabti B, et al. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003 Feb; 13 (2): 377-88
69. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001 Nov; 43 (4): 226-33
70. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997 Jul 3; 337 (1): 15-21
71. Sabbatani S, Manfredi R, Pavoni M, et al. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004 Aug; 158 (2): 165-71
72. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005 Oct; 56 (4): 745-55
73. Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002 Sep 15; 35 (6): 769-72
74. Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, DC: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005 Feb 1; 40 (3): 477-9
75. Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005 Feb 1; 40 (3): 480-2
76. Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999 Mar; 28 (3): 629-33
77. Woodworth GF, McGirt MJ, Williams MA, et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegaly secondary to HIV-associated cryptococcal meningitis. Surg Neurol 2005 Jun; 63 (6): 529-31; discussion 31-2
78. Lionakis MS, Lewis RE, Torres HA, et al. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005 May; 52 (1): 15-20
79. Mylonakis E, Paliou M, Sax PE, et al. Central nervous system aspergillosis in patients with human immunodeficiency virus infection: report of 6 cases and review. Medicine 2000 Jul; 79 (4): 269-80
80. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005 May; 43 Suppl. 1: S49-58
81. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002 Jan; 33 (1): 116-24
82. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990 Nov-Dec; 12 (6): 1147-201
83. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 Feb 1; 32 (3): 358-66
84. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34 (1): 7-14
85. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999 Oct; 37 (10): 3223-8
86. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001 Mar 15; 97 (6): 1604-10
87. Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin- tazobactam: how much and to what extent? Antimicrob Agents Chemother 2005 Sep; 49 (9): 3984-5
88. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002 Apr; 40 (4): 1496-9
89. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005 Oct; 5 (10): 609-22
90. Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001 Apr; 66 (4): 257-62
91. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30 (4): 696-709
92. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 Oct 15; 106 (8): 2641-5
93. Steinbach WJ, Benjamin Jr DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004 Jul 15; 39 (2): 192-8
94. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005 Sep 1; 41 (5): 634-53
95. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004 Feb 26; 350 (9): 950-2
96. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 Apr 15; 191 (8): 1350-60
97. Warwar RE, Bullock JD. Rhino-orbital-cerebral mucormycosis: a review. Orbit 1998 Dec; 17 (4): 237-45
98. Sundaram C, Mahadevan A, Laxmi V, et al. Cerebral zygomycosis. Mycoses 2005 Nov; 48 (6): 396-407
99. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004 Feb; 89 (2): 207-14
100. Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004 Jul; 45 (7): 1351-60
101. Pagano L, Caira M, Falcucci P, et al. Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther 2005 Oct; 3 (5): 775-85
102. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005 May 1; 40 Suppl. 6: S401-8
103. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 Jan; 50 (1): 126-33
104. Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole (POS) experience in the treatment of zygomycosis [abstract no. M-1757]. In: Proceedings of the 43rd Annual Meeting on Infectious Diseases; 2003 Sep 14-17; Chicago (IL): 476
105. Van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006 Apr 1; 42 (7): E61-5
106. Gugnani HC. Histoplasmosis in Africa: a review. Indian J Chest Dis Allied Sci 2000 Oct-Dec; 42 (4): 271-7
107. Ashford DA, Hajjeh RA, Kelley MF, et al. Outbreak of histoplasmosis among cavers attending the National Speleological Society Annual Convention, Texas, 1994. Am J Trop Med Hyg 1999 Jun; 60 (6): 899-903
108. Jones TF, Swinger GL, Craig AS, et al. Acute pulmonary histoplasmosis in bridge workers: a persistent problem. Am J Med 1999 Apr; 106 (4): 480-2
109. Vail GM, Young RS, Wheat LJ, et al. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 2002 Sep; 4 (3): 148-51
110. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis: Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30 (4): 688-95
111. Couppie P, Sobesky M, Aznar C, et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clin Infect Dis 2004 Jan 1; 38 (1): 134-8
112. Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005 Mar 15; 40 (6): 844-52
113. Wheat LJ, Connolly P, et al. False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies. Transpl Infect Dis 2004 Mar; 6 (1): 23-7
114. Hecht FM, Wheat J, Korzun AH, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997 Oct 1; 16 (2): 100-7
115. Clark B, Foster R, Tunbridge A, et al. A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole. J Infect 2005; 51 (3): E177-180
116. Gilchrist TC. A case of blastomycetic dermatitis in man. The Johns Hopkins Hospital Reports 1896; 1: 269-90
117. Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med 1993 Oct 21; 329 (17): 1231-6
118. Lemos LB, Guo M, Baliga M. Blastomycosis: organ involvement and etiologic diagnosis: a review of 123 patients from Mississippi. Ann Diagn Pathol 2000 Dec; 4 (6): 391-406
119. Centers for Disease Control and Prevention. Blastomycosis: Wisconsin, 1986-1995. MMWR Morb Mortal Wkly Rep 1996 Jul 19; 45 (28): 601-3
120. Chapman SW, Bradsher Jr RW, Campbell Jr GD, et al. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30 (4): 679-83
121. Chowfin A, Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin Infect Dis 2000 Jun; 30 (6): 969-71
122. Pearson GJ, Chin TW, Fong IW. Case report: treatment of blastomycosis with fluconazole. Am J Med Sci 1992; 303 (5): 313-5
123. Bakleh M, Aksamit AJ, Tleyjeh IM, et al. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis 2005; 40 (9): E69-71
124. Ward BA, Parent AD, Raila F. Indications for the surgical management of central nervous system blastomycosis. Surg Neurol 1995 Apr; 43 (4): 379-88
125. Johnson RH, Einstein HE. Coccidioidal meningitis. Clin Infect Dis 2006 Jan 1; 42 (1): 103-7
126. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005 Nov 1; 41 (9): 1217-23
127. Fisher MC, Koenig GL, White TJ, et al. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002; 94: 73-84
128. Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005 Jan 10; 165 (1): 113-7
129. Crum NF, Lederman ER, Hale BR, et al. A cluster of disseminated coccidioidomycosis cases at a US military hospital. Mil Med 2003 Jun; 168 (6): 460-4
130. Arsura EL, Johnson R, Penrose J, et al. Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis 2005 Feb 15; 40 (4): 624-7
131. Ragland AS, Arsura E, Ismail Y, et al. Eosinophilic pleocytosis in coccidioidal meningitis: frequency and significance. Am J Med 1993 Sep; 95 (3): 254-7
132. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med 1993 Jul 1; 119 (1): 28-35
133. Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 Jun 1; 40 (11): 1684-8
134. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996 Feb 1; 124 (3): 305-10
135. Corredor GG, Peralta LA, Castano JH, et al. The naked-tailed armadillo Cabassous centralis (Miller 1899): a new host to Paracoccidioides brasiliensis. Molecular identification of the isolate. Med Mycol 2005 May; 43 (3): 275-80
136. de Almeida SM. Central nervous system paracoccidioidomycosis: an overview. Braz J Infect Dis 2005 Apr; 9 (2): 126-33
137. Nobre V, Braga E, Rayes A, et al. Opportunistic infections in patients with AIDS admitted to an university hospital of the Southeast of Brazil. Rev Inst Med Trop Sao Paulo 2003 Mar-Apr; 45 (2): 69-74
138. da Silva SH, Colombo AL, Blotta MH, et al. Diagnosis of neuroparacoccidioidomycosis by detection of circulating antigen and antibody in cerebrospinal fluid. J Clin Microbiol 2005 Sep; 43 (9): 4680-3
139. de Almeida SM, Queiroz-Telles F, Teive HA, et al. Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings. J Infect 2004 Feb; 48 (2): 193-8
140. Shikanai-Yasuda MA, Benard G, Higaki Y, et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol 2002 Aug; 40 (4): 411-7
141. Segretain G. Penicillium marneffei n. sp., agent of a mycosis of the reticuloendothelial system. Mycopathologia 1959 Nov 30; 11: 327-53
142. Noritomi DT, Bub GL, Beer I, et al. Multiple brain abscesses due to Penicillium spp infection. Rev Inst Med Trop Sao Paulo 2005 May-Jun; 47 (3): 167-70
143. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003 Dec; 16 (6): 607-12
144. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997 Aug 1; 90 (3): 999-1008
145. Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003 Dec 15; 76 (11): 1632-7
146. Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000 Sep; 31 (3): 673-7
147. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole: case report. J Neurosurg 2005 Jul; 103 (1 Suppl.): 83-7
148. Heyn K, Tredup A, Salvenmoser S, et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005 Dec; 49 (12): 5157-9
149. Wagner D, Sander A, Bertz H, et al. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 2005 Oct; 33 (5-6): 397-400
150. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004 Jan 15; 38 (2): 206-16
151. Podnos YD, Anastasio P, De La Maza L, et al. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report. Neurosurgery 1999 Aug; 45 (2): 372-5
152. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005 Feb; 43 (1): 91-5
153. Singh N, Chang FY, Gayowski T, et al. Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clin Infect Dis 1997 Mar; 24 (3): 369-74
154. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004 Mar; 10 Suppl. 1: 48-66